SF3B1 and B-cell chronic lymphocytic leukemia: Considering that the mutation is frequently seen in myelodysplastic syndrome (MDS), chronic lymphocytic leukemia (CLL) and breast cancer our results can be used to study other cancer types, and mutant SF3B1 can be considered a potential drug target for cancer therapy.